Bausch + Lomb (BLCO) Expected to Announce Quarterly Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Wednesday, April 30th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $1.15 billion for the quarter. Bausch + Lomb has set its FY 2025 guidance at EPS.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last posted its earnings results on Wednesday, February 19th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.02. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The firm had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same period last year, the firm posted $0.24 EPS. The firm's revenue for the quarter was up 9.1% on a year-over-year basis. On average, analysts expect Bausch + Lomb to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bausch + Lomb Price Performance

Shares of BLCO traded down $0.20 during mid-day trading on Monday, reaching $13.53. 260,189 shares of the company's stock were exchanged, compared to its average volume of 623,805. The company has a quick ratio of 1.01, a current ratio of 1.60 and a debt-to-equity ratio of 0.72. Bausch + Lomb has a 52-week low of $10.46 and a 52-week high of $21.69. The company has a market cap of $4.78 billion, a price-to-earnings ratio of -14.86, a PEG ratio of 0.85 and a beta of 0.54. The company has a 50-day simple moving average of $14.26 and a two-hundred day simple moving average of $17.14.

Wall Street Analyst Weigh In

BLCO has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating and issued a $23.00 price target on shares of Bausch + Lomb in a report on Tuesday, February 18th. Stifel Nicolaus decreased their price target on Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating on the stock in a research note on Thursday, April 3rd. Bank of America dropped their price objective on shares of Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating for the company in a research note on Thursday, February 20th. Wells Fargo & Company reissued an "equal weight" rating and issued a $15.00 target price (down from $24.00) on shares of Bausch + Lomb in a research report on Friday, March 28th. Finally, Needham & Company LLC restated a "hold" rating on shares of Bausch + Lomb in a report on Thursday. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $18.82.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.